Skip to main content

Abivax S.A.

ABVX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001956827

No open-market purchases or sales by Abivax S.A. insiders were filed in the last 90 days; 318 institutions reported holding it in 13F filings for Q3 2026, worth $5.64B in total; no superinvestor holds it.

Other share classesAAVXF

Currency
EUR
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 8, 2026, 3:06 PM ET

Amounts are in EUR, the currency Abivax S.A. reports in. Lines marked ≈ US$ convert key figures to US dollars.

Revenue flow, FY2025

Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.

Net loss for FY2025: EUR 336.1M (7354.5% of revenue).

Income statement

Each column is one fiscal year, newest first.

Income statement of Abivax S.A., annual
Line itemFY2025FY2024FY2023
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023
Filing20-F20-F20-F
Reported–––
RevenueEUR 4.57M≈ US$5.17MEUR 12.4M≈ US$13.5MEUR 4.62M≈ US$5.00M
Operating expensesEUR 250.6MEUR 185.4MEUR 132.0M
Research and developmentEUR 177.8MEUR 146.5MEUR 103.2M
Selling, general and administrativeEUR 67.7MEUR 32.9MEUR 22.4M
Operating incomeEUR -246.1MEUR -173.0MEUR -127.4M
Interest expenseEUR 111.7MEUR 17.0MEUR 27.9M
Income taxEUR 5.85MEUR 0EUR 0
Net incomeEUR -336.1M≈ US-$380.0MEUR -176.2M≈ US-$190.7MEUR -147.7M≈ US-$159.8M
EPS, basicEUR -4.83EUR -2.80EUR -3.43
EPS, dilutedEUR -4.83EUR -2.80EUR -3.43
Weighted shares, basic69.5M63.0M43.1M
Weighted shares, diluted69.5M63.0M43.1M
Margins and growth
Operating margin-5384.2%-1389.5%-2756.5%
Net margin-7354.5%-1415.7%-3197.1%
Revenue growth, year over year−63.3%+169.4%–

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Abivax S.A., annual
Line itemFY2025FY2024FY2023
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023
Filing20-F20-F20-F
Reported–––
Cash and equivalentsEUR 516.7MEUR 144.2MEUR 251.9M
Total current assetsEUR 551.2MEUR 170.7MEUR 286.0M
GoodwillEUR 18.4MEUR 18.4MEUR 18.4M
Intangible assetsEUR 6.61MEUR 6.61MEUR 6.60M
Total assetsEUR 584.3M≈ US$685.8MEUR 205.2M≈ US$212.4MEUR 327.1M≈ US$361.8M
Accounts payableEUR 37.6MEUR 43.8MEUR 47.2M
Total current liabilitiesEUR 63.0MEUR 94.0MEUR 70.0M
Shareholders' equityEUR 455.2MEUR 40.6MEUR 196.0M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Abivax S.A., annual
Line itemFY2025FY2024FY2023
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023
Filing20-F20-F20-F
Reported–––
Operating cash flowEUR -161.1M≈ US-$182.2MEUR -154.1M≈ US-$166.7MEUR -97.1M≈ US-$105.1M
Capital expendituresEUR 142.0KEUR 640.0KEUR 265.0K
Free cash flowEUR -161.3M≈ US-$182.3MEUR -154.7M≈ US-$167.4MEUR -97.4M≈ US-$105.3M
Stock-based compensationEUR 35.4MEUR 20.2MEUR 8.18M
Investing cash flowEUR -8.19MEUR 15.8MEUR -8.10M
Financing cash flowEUR 547.3MEUR 28.2MEUR 335.3M
Net change in cashEUR 372.5MEUR -107.7MEUR 225.0M
Ratio
Stock-based compensation, % of revenue774.6%162.5%177.0%

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Abivax S.A. by cover date
Cover dateShares outstandingChange in a yearFiling
Dec 31, 202578.5M+24.0%SEC
Dec 31, 202463.3M+0.7%SEC
Dec 31, 202362.9M–SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
  • ≈ US$ figures convert EUR at FRED H.10 exchange rates (Federal Reserve): the average rate over the period for income and cash flow, and the rate on the period-end date, or the last business day before it, for the balance sheet.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS. Their cover share count adds up the classes but only for the last few filings, so there can be a gap before them.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.